These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6715088)

  • 1. Effect of procetofen on serum lipids and apoproteins.
    Capurso A; Mogavero AM; Taverniti R; Resta F; Pace L; Bonomo L
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):194-7. PubMed ID: 6715088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen.
    Micheli H; Pometta D; Gustafson A
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):503-6. PubMed ID: 528097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of procetofen on apolipoprotein A I and B concentrations in hyperlipoproteinemia.
    Viikari J; Solakivi-Jaakkola T; Lehtonen A
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):362-5. PubMed ID: 6811447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 8. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of procetofen on lipoproteins and blood lipids in patients with hyperlipemia].
    Abaurre R; Vega J; Maneschi E; Bernabe H
    Medicina (B Aires); 1980; 40(6 Pt 2):896. PubMed ID: 7219169
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
    Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
    Zeman M; Zák A; Tvrzická E; Konárková M; Stípek S
    Cas Lek Cesk; 2002 Apr; 141(7):211-6. PubMed ID: 12053756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Modification of serum lipids, lipoproteins and apoproteins AI and B in patients with hyperlipidemia Type IIa and IIb using polyenylphosphatidylcholine].
    Noseda G; Suvà F; Fragiacomo C
    Schweiz Med Wochenschr; 1985 Jul; 115(30):1064-70. PubMed ID: 4035328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamsters. Influence of fenofibrate.
    Plancke MO; Olivier P; Clavey V; Marzin D; Fruchart JC
    Methods Find Exp Clin Pharmacol; 1988 Sep; 10(9):575-9. PubMed ID: 3226223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of the PSMF diet on plasma lipids and lipoproteins in obese subjects].
    Petrillo A; Chevaux F; Rohrer J; Darioli R
    Schweiz Med Wochenschr; 1984 Dec; 114(49):1837-41. PubMed ID: 6515380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
    Micheli H; Pometta D; Gustafson A
    Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.